An interventional study of No-nap and 15-min nap in Shift Work, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by University of Pittsburgh · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.
Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 9th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 27th registered.
53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.
Browse Idiopathic Hypersomnia studies →12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
Takeda · Sites in United States, Australia, China and 2 more countries
Ages 18–71
Harmony Biosciences Management, Inc. · Sites in United States, Canada
Ages 18+
Centessa Pharmaceuticals (UK) Limited · Sites in United States, Canada, Italy and 1 more country
Ages 18–65
Takeda · Sites in United States, France, Hong Kong and 3 more countries
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is above the median of 82 across 40 interventional studies indexed under Idiopathic Hypersomnia.
Median enrollment 100 across the 27 interventional studies, 100 across the 3 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 30 have an industry lead sponsor. The 10 most frequent:
University of Pittsburgh is the lead sponsor of 1,422 studies on the registry; 170 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
University of Pittsburgh has 1 study filed under Idiopathic Hypersomnia — fewer than ten, so there is no comparison to draw.
5 of the studies in Idiopathic Hypersomnia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500090Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) | 2027-10 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
| NCT06812078TakedaA Study of TAK-360 in Adults With Idiopathic Hypersomnia | 2026-11-30 |
| NCT06752668Centessa Pharmaceuticals (UK) LimitedA Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | 2026-12 |
| NCT05837091Mayo ClinicLow Sodium Oxybate in Patients With Idiopathic Hypersomnia | 2027-01-29 |
Add all 5 to your calendar (.ics) → With an account.
Among the 30 studies in Idiopathic Hypersomnia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Night shift work schedules disrupt sleep and have a negative impact on cardiovascular health. Most who work in public safety occupations and in healthcare work night shifts. These workers experience abnormal blood pressure during night shifts and are at greater risk of cardiovascular disease. Napping during night shifts can help to restore blood pressure patterns to a more normal pattern and may help to reduce risk of cardiovascular disease. Naps may also have an impact on alertness and performance immediately upon waking. The overarching goal of this study is to determine which duration of a nap taken during simulated night shift work has the greatest impact blood pressure and post-nap performance.
Researchers will compare 5 nap durations to see which has the greatest impact on blood pressure patterns and post-nap psychomotor performance.
Researchers hypothesize that longer naps will lead to improved blood pressure outcomes and shorter naps will contribute to better performance after waking.
Findings will help employers and employees who work night shifts determine how best to incorporate brief naps during night shift work.
Blunted blood pressure (BP) dipping is a well-described risk factor for cardiovascular disease (CVD) among older adults and individuals with chronic disease. Previous research shows that night shift workers are at risk and repeatedly exposed to blunted BP dipping as a consequence of sleep loss and irregular sleep. While occasional episodes of blunted BP dipping may not be harmful, repetitive exposure over years of night shift work, as experienced by public safety workers (PSWs) and healthcare workers (HCWs), is likely detrimental to cardiovascular health and increases risk of CVD. Recent research shows that exposure can be mitigated with brief on-duty naps, which briefly restore normal BP dipping. Despite these data, there is legitimate clinical equipoise regarding the optimal on-duty nap duration (dose) needed to maximize BP dipping and minimize threats to post-nap psychomotor performance (i.e., sleep inertia).
This study will use a Phase II, within subject, crossover, incomplete block randomized trial design to test the efficacy of 5 overnight on-duty nap conditions: no-nap, 15, 30, 45, and 60-minutes. The primary outcome is the proportion of participants with a clinically meaningful greater than or equal to 10% dip in BP during nap opportunities. The secondary outcome is focused on deficits in psychomotor performance at greater than or equal to 10 mins post-nap: a safety-critical moment for PSWs and HCWs.
Goal enrollment is set at 130, accounting for attrition. Each condition begins with 36 hours of at-home monitoring with non-invasive devices. The last 12 hours of each condition includes a 12-hour simulated night shift with nap opportunities provided at 0200 hours with the nap duration determined by the randomization schema. During the simulated night shift, participants will be continuously monitored with non-invasive devices, allowed to consume controlled amounts of caffeine, and complete standardized tests of psychomotor performance. Participants will be blinded to nap duration and caffeine dose. Volunteer participants will be asked to complete 4 of the 5 nap conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
5 x 4 x 3 x 2 = 120 possible orderings of the 5 interventions for each person.
Behavioral: No-nap · Behavioral: 15-min nap · Behavioral: 30-min nap · Behavioral: 45-min nap · Behavioral: 60-min nap
No-nap opportunity offered
A 15-minute nap opportunity at 02:00am
A 30-minute nap opportunity at 02:00am
A 45-minute nap opportunity at 02:00am
A 60-minute nap opportunity at 02:00am
BP dipping
The ratio of mean sleep to mean wake blood pressure (BP) by taking the difference between the mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) during nap opportunities, and the mean SBP and DBP during wake periods.
Time frame: During simulated night shift, 12 hours
Psychomotor performance post-nap
Severe psychomotor impairment post-nap as measured by the Psychomotor Vigilance Test Brief (PVT-B)
Time frame: During simulated night shift, greater than or equal to 10 minutes post intervention nap
Performance on simulated patient scenarios
Change in performance pre-to-post nap. Performance rated from 0-100 with higher scores indicating better performance. Positive change indicates improved performance.
Time frame: During simulated night shift, 12 hours
Plan to share: Yes — All collected IPD
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: No later than 3 years after completing the last follow-up of the last participant.
Access criteria: Access through NHLBI BioLINCC repository
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Aug 2030, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.